The new testing capability will include dedicated microbiology laboratories as well as temperature and humidity-controlled stability storage capabilities
Symbiosis Pharmaceutical Services (Symbiosis), an international contract manufacturing organisation (CMO) with headquarters in the UK, who specialise in providing GMP aseptic fill and finish services for biologic and small molecule pharmaceuticals to biotechnology and pharmaceutical companies worldwide, has announced a 1 million GBP (1.2 million Euros, 1.3 million USD) investment in its in-house analytical services capabilities.This investment will see the introduction of in-house testing capabilities for both analytical chemistry and microbiology and further enable Symbiosis to meet its ambitious growth plans.
The new testing capability will include dedicated microbiology laboratories as well as temperature and humidity-controlled stability storage capabilities, to be located adjacent to Symbiosis’ existing GMP manufacturing suites in Stirling, Scotland.
Symbiosis also announced the recruitment of Alison Clayton PhD, an experienced senior leader in the CRO and life sciences industry, who joined Symbiosis as Head of Analytical Services to lead this initiative to significantly extend analytical testing capabilities at Symbiosis.
Head of Analytical Services, Alison Clayton commented: “Symbiosis will have a phased approach to building in-house chemistry and microbiology laboratory capabilities so that we can deliver the most appropriate and value-adding assays and testing that our clients demand of us.
“Symbiosis will offer an enhanced suite of testing capabilities, including sterility, bioburden and endotoxin testing as well as analytical chemistry. Ultimately, this will allow our clients to achieve their tight drug development project timelines.”
Click here to read more.